Payment overview · 2025
General Payments
$117.81
5 reported records · 3 companies
Healthcare provider profile · identity verified
Ju Hwan Lee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BAKERSFIELD, CA · NPI 1619969847
Verified facts
What the public records show
CMS Open Payments records show Ju Hwan Lee, MD received $117.81 in general payments during 2025 across 5 reported records.
Novartis Pharmaceuticals Corporation accounted for 45.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.70 | 45.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.79 | 40.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.32 | 13.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.81 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $53.70 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.79 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 203 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
203 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 172 |
| Losartan Potassium | Losartan Potassium | 299 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 63 |
| Furosemide | Furosemide | 205 | 77 |
| Eliquis | Apixaban | 203 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 66 |
| Carvedilol | Carvedilol | 162 | 46 |
| Gabapentin | Gabapentin | 156 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 45 |
| Lisinopril | Lisinopril | 131 | 42 |
| Sertraline Hcl | Sertraline Hcl | 130 | 37 |
| Potassium Chloride | Potassium Chloride | 125 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 48 |
| Metformin Hcl | Metformin Hcl | 115 | 43 |
| Jardiance | Empagliflozin | 85 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 24 |
| Omeprazole | Omeprazole | 63 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 15 |
| Allopurinol | Allopurinol | 58 | 18 |
| Spironolactone | Spironolactone | 58 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 20 |
| Alendronate Sodium | Alendronate Sodium | 56 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 17 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 16 |
| Januvia | Sitagliptin Phosphate | 46 | 12 |
| Prednisone | Prednisone | 45 | 24 |
| Bumetanide | Bumetanide | 43 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 11 |
| Glipizide | Glipizide | 41 | 14 |
| Famotidine | Famotidine | 40 | 15 |
| Ondansetron Odt | Ondansetron | 39 | 15 |
| Trulicity | Dulaglutide | 39 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Lactulose | Lactulose | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | 11 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | 11 |
| Finasteride | Finasteride | 29 | 11 |
| Midodrine Hcl | Midodrine Hcl | 29 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 29 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | 11 |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | 12 |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.81 · 5 records | Novartis Pharmaceuticals Corporation | AREXVY, ELIQUIS, LEQVIO, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error